Link: Journal of Antimicrobial Chemotherapy.
Among 133 patients with a diabetic ulcer infection, 103 were clinically evaluable; 47 received daptomycin and 56 received a comparator. Most infections were monomicrobial, and Staphylococcus aureus was the predominant pathogen. Success rates for patients treated with daptomycin or the comparators were not statistically different for clinical (66% versus 70%, respectively; 95% CI, –14.4, 21.8) or microbiological (overall or by pathogen) outcomes. Both treatments were generally well tolerated, with most adverse events of mild to moderate severity.
Conclusions:
The clinical and microbiological efficacy and safety of daptomycin were similar to those of commonly used comparator antibiotics for treating infected diabetic foot ulcers caused by Gram-positive pathogens. Daptomycin should be considered for treating these infections, especially those caused by resistant Gram-positive pathogens.
Keywords: diabetic ulcers , foot infections , soft tissue infections , antibiotic resistance , Gram-positive infections
{ 2 comments… read them below or add one }
We can help you find out about the drug if you have the name but we don’t have access to information on the BRI trial
My husband was given a trial drug in the BRI approx 2½ years ago. I am trying to find out the name of the drug to see what side affects have been reported. Can you help.